Literature DB >> 15610018

Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses.

Sushma Yadav1, Sharad S Singhal, Jyotsana Singhal, Dilki Wickramarachchi, Eugene Knutson, Thomas B Albrecht, Yogesh C Awasthi, Sanjay Awasthi.   

Abstract

RLIP76 (RALBP1) is a multifunctional transporter involved in signaling and transmembrane movement of solute allocrites, which include glutathione conjugates and several natural product antineoplastic agents [Awasthi, S., et al. (2000) Biochemistry 39, 9327-9334; (2001) Biochemistry 40, 4159-4168]. Our previous studies suggested that the membrane-anchoring domain resides in the N-terminus of RLIP76, despite the lack of identifiable membrane-spanning domains. Amino acid sequence analysis indicated that this region of RLIP76 contains sequences that are similar to those of vector peptides. We, therefore, have studied the effect of a series of deletion mutant proteins on hydrophobicity and transport activity. RLIP76 or one of its derived deletion mutants was expressed in Escherichia coli, and bacteria were lysed and extracted in buffer without or with the nonionic detergent polidocanol. The ratio of RLIP76 in the detergent/aqueous extracts was found to be 2.5 for the wild-type protein, but decreased to 0.7 in the mutant in which amino acids 154-219 were deleted. Deletion of only one segment of this region (amino acids 171-185) alone resulted in a significant decrease in this ratio to 1.0. For the mutants with deletions within the region from amino acid 154 to 219, loss of hydrophobicity correlated with less incorporation of mutants into artificial liposomes, and decreased transport activity toward doxorubicin and dinitrophenyl-S-glutathione. In contrast, deletion of one of the two ATP-binding sites (at amino acids 65-80 or 415-448) or both sites did not affect hydrophobicity but reduced or abrogated transport activity. NSCLC (H358) stably transfected with del171-185 and del154-219 showed that loss of these regions results in a decrease in the extent of membrane association of RLIP76. Confocal laser immunohistochemistry colocalized amino acids 171-185 with her2/neu on the cell surface. Depletion of wild-type RLIP76 using si-RNA directed to this region in cells transfected with del171-185 resulted in the loss of cell surface expression. These finding demonstrate that amino acids 171-185 constitute a cell surface epitope which is necessary for optimal transport of anthracycline and glutathione conjugates by RLIP76, and that this peptide could be a novel target for antineoplastic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610018     DOI: 10.1021/bi0482811

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

Review 1.  Role of RLIP76 in doxorubicin resistance in lung cancer.

Authors:  Rit Vatsyayan; Pankaj Chaudhary; Poorna Chandra Rao Lelsani; Preeti Singhal; Yogesh C Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

2.  hSET1: a novel approach for colon cancer therapy.

Authors:  Sushma Yadav; Jyotsana Singhal; Sharad S Singhal; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2009-03-06       Impact factor: 5.858

3.  Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.

Authors:  Kian-Huat Lim; Donita C Brady; David F Kashatus; Brooke B Ancrile; Channing J Der; Adrienne D Cox; Christopher M Counter
Journal:  Mol Cell Biol       Date:  2009-11-09       Impact factor: 4.272

4.  Targeting p53-null neuroblastomas through RLIP76.

Authors:  Jyotsana Singhal; Sushma Yadav; Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Sharad S Singhal; Sanjay Awasthi
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-16

5.  mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Authors:  Amith Panner; Jean L Nakamura; Andrew T Parsa; Pablo Rodriguez-Viciana; Mitchel S Berger; David Stokoe; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

6.  Mitogenic and drug-resistance mediating effects of PKCalpha require RLIP76.

Authors:  Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Biochem Biophys Res Commun       Date:  2006-07-28       Impact factor: 3.575

7.  Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis.

Authors:  Paola Margutti; Paola Matarrese; Fabrizio Conti; Tania Colasanti; Federica Delunardo; Antonella Capozzi; Tina Garofalo; Elisabetta Profumo; Rachele Riganò; Alessandra Siracusano; Cristiano Alessandri; Bruno Salvati; Guido Valesini; Walter Malorni; Maurizio Sorice; Elena Ortona
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 8.  RLIP76: A novel glutathione-conjugate and multi-drug transporter.

Authors:  Sharad S Singhal; Sushma Yadav; Cherice Roth; Jyotsana Singhal
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

Review 9.  RLIP76 and Cancer.

Authors:  Sanjay Awasthi; Sharad S Singhal; Yogesh C Awasthi; Bryan Martin; Jung-Hee Woo; C Casey Cunningham; Arthur E Frankel
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  Trastuzumab in the management of early and advanced stage breast cancer.

Authors:  Rupert Bartsch; Catharina Wenzel; Guenther G Steger
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.